Market Overview The bone metastasis market is expanding as skeletal-related event prevention guides breast cancer adjuvant strategy, with bone-modifying agents now recommended not only for established metastatic disease but also for adjuvant bone protection in postmenopausal women receiving aromatase inhibitor therapy. Zoledronic acid and denosumab counteract treatment-induced bone loss,...